SIGNABLOK
SignaBlok is a biopharmaceutical company, that provides signaling chain homooligomerization platform basics, macrophage modulation, macrophage imaging, pipeline, therapeutic programs for autoimmune diseases, atherosclerosis, retinopathy, sepsis, ARDS, and covid, science, and management develops novel targeted therapeutics and delivery nanosystems.
SIGNABLOK
Social Links:
Industry:
Biopharma Biotechnology Consulting Nanotechnology Therapeutics
Founded:
2009-01-01
Address:
Shrewsbury, Massachusetts, United States
Country:
United States
Website Url:
http://www.signablok.com
Total Employee:
1+
Status:
Active
Contact:
+1 508 792 4589
Email Addresses:
[email protected]
Official Site Inspections
http://www.signablok.com Semrush global rank: 5.18 M Semrush visits lastest month: 1.56 K
- Host name: 173.231.211.74
- IP address: 173.231.211.74
- Location: El Segundo United States
- Latitude: 33.9214
- Longitude: -118.413
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90245
More informations about "SignaBlok"
Homepage - SignaBlok
SignaBlok, Inc. is a biopharmaceutical company on a fast track to success. Founded in 2009 to develop novel targeted therapeutics and delivery nanosystems through the use of our revolutionary science and technologies, … See details»
SignaBlok - Crunchbase Company Profile & Funding
SignaBlok is a biopharmaceutical company, that provides signaling chain homooligomerization platform basics, macrophage modulation, macrophage … See details»
SignaBlok 2025 Company Profile: Valuation, Funding & Investors
SignaBlok General Information Description. Operator of a biotech company intended to develop therapeutics that employ unique mechanisms of blocking cell receptor signaling in the context … See details»
SIGNABLOK, INC. Company Profile | Worcester, MA | Competitors ...
Signablok, inc. d&b business directory home / business directory / professional, scientific, and technical services / scientific research and development services / united states / … See details»
Signablok Company Profile - Office Locations, Competitors ... - Craft
Signablok is a biopharmaceutical company that develops mechanism-based targeted therapeutics and delivery nanosystems. It provides a signaling chain homooligomerization drug discovery … See details»
SignaBlok, Inc. - CMOCRO
SignaBlok, Inc. is a biopharmaceutical company focused on developing first-in-class, novel targeted therapies and diagnostics for cancer, arthritis, retinopathy ... See details»
About Us - SignaBlok
SignaBlok, Inc. is a biopharmaceutical company founded in 2009 to develop novel mechanism-based targeted therapeutics and delivery nanosystems through the use of our revolutionary … See details»
SignaBlok, Inc. - VentureRadar
SignaBlok has an expanding, deep and diversified pipeline of new chemical entity (NCE) assets leveraging SignaBlok's proprietary technologies to image macrophages and shape their … See details»
SignaBlok - Overview, News & Similar companies | ZoomInfo.com
Who is SignaBlok. SignaBlok, Inc. is a biopharmaceutical company on a fast track to success. Founded in 2009 to develop novel targeted therapeutics and delivery nano systems through … See details»
SignaBlok, Inc. - Latest News - signablok | PRLog
View SignaBlok, Inc.'s latest news on PRLog, with news from 400,000 organizations. SignaBlok, Inc. has 8 news items. SignaBlok is developing a new class of therapies that can have broad … See details»
Signablok Corporate Headquarters, Office Locations and …
Signablok Headquarters and Office Locations. Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit. Button CTA. Signablok is headquartered in Worcester, 61 Frank St … See details»
SIGNABLOK, INC. | SBIR.gov
Project Summary/Abstract Retinal neovascularization (RNV) is a major cause of vision loss in retinopathy of prematurity (ROP), diabetic retinopathy (DR) and retinal vein occlusion. See details»
Technology - SignaBlok
SignaBlok’s pipeline development is led by programs to develop SCHOOL inhibitors for TREM-1 and TREM-2 receptors, focused on inflammation-associated diseases and disorders. We are … See details»
History - SignaBlok
This discovery opens new avenues for drug development with applications in many serious diseases. Read More See details»
Partners & Collaborators - SignaBlok
SignaBlok is discovering and developing innovative, first-in-class therapeutic and diagnostic agents for modulation and visualization of inflammatory immune response to benefit patients … See details»
Pipeline - SignaBlok
SignaBlok has an expanding, deep and diversified pipeline of new chemical entity (NCE) assets leveraging SignaBlok's proprietary technologies to image macrophages and shape their … See details»
SignaBlok Company Profile | Management and Employees List
SignaBlok Profile and History . SignaBlok, Inc. is a biopharmaceutical company on a fast track to success. Founded in 2009 to develop novel targeted therapeutics and delivery nanosystems … See details»
Signablok Inc - Company Profile and News - Bloomberg Markets
Company profile page for Signablok Inc including stock price, company news, executives, board members, and contact information See details»
Signablok | Nanotechnology Company | NPD
SignaBlok About Company signablok is a biopharmaceutical company, that provides signaling chain homooligomerization platform basics, macrophage modulation, macrophage imaging, … See details»
Signablok, Inc. To Present Preclinical Data on Trem-1-Targeting …
Mar 18, 2025 SignaBlok, Inc. is a Massachusetts-based biotechnology company founded in 2009 to develop innovative, first-in-class therapeutics for targeted treatment of inflammation … See details»